Intravenous Carbetocin to decrease blood loss during open myomectomy: a randomized placebo-controlled study


  • Hany F. Sallam Department of Obstetrics and Gynecology, Faculty of Medicine, Aswan University, Egypt
  • Nahla W. Shady Department of Obstetrics and Gynecology, Faculty of Medicine, Aswan University, Egypt



Carbetocin, Myomectomy


Background: Uterine leiomyomas are benign tumors of the uterus, which represent the most common neoplasms in women of reproductive age, and have a lifetime incidence of approximately 70% in the general population. The objective of this study was to assess the effect of using a single pre-operative dose of IV 100 μg Carbetocin on intra-operative blood loss in abdominal myomectomy surgeries.

Methods: In a randomized double-blind placebo-controlled trial, 86 women undergoing abdominal myomectomy for symptomatic uterine leiomyomas were randomly assigned to receive a single dose of pre-operative of IV 100 μg Carbetocin (n = 43) or placebo (n = 43) just before the operation. The primary outcome was intra-operative blood loss.

Results: Intra-operative blood loss was significantly lower in those women randomized to receive IV Carbetocin versus the placebo group (714.19±186.27 ml versus 1033.49±140.9 ml), p = 0.0001 The incidence of blood transfusion was increased in placebo group (69.8%) compared with (18.6%) in Carbetocin group, (P = 0.0001). Also, there was a significant reduction in operative time in Carbetocin group (66.35%±10.18) compared with placebo group (95.95±9.16), (P = 0.0001).

Conclusions: A single pre-operative dose of IV Carbetocin (100 μg) is a simple applicable method for reducing intra-operative blood loss and operative time in abdominal myomectomy.


Marsh EE, Ekpo GE, Cardozo ER, Brocks M, Dune T, Cohen LS. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study. Fertility and Sterility. 2013;99(7):1951-7.

Taylor A, Sharma M, Tsirkas P, Di Spiezio Sardo A, Setchell M, Magos A. Reducing blood loss at open myomectomy using triple tourniquets: a randomized controlled trial. Br J Obstet Gynaecol. 2005;112:340-5.

Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2011:Cd005355.

Atashkhoei S, Fakhari S, Pourfathi H, Bilehjani E, Garabaghi PM, Asiaei A. Effect of oxytocin infusion on reducing the blood loss during abdominal myomectomy: a double-blind randomised controlled trial. BJOG. 2016;124:292-8

Busnelli M, Rimoldi V, Vigano P, Persani L, Di Blasio AM, Chini B. Oxytocin-induced cell growth proliferation in human myometrial cells and leiomyomas. Fertil Steril. 2010;94:1869-74.

Agostini A, Ronda I, Franchi F, Bretelle F, Roger V, Cravello L, et al: Oxytocin during myomectomy: a randomized study. Eur J Obstet Gynecol Reprod Biol 2005;118:235-8.

Wang CJ, Lee CL, Yuen LT, Kay N, Han CM, Soong YK. Oxytocin infusion in laparoscopic myomectomy may decrease operative blood loss. J Minim Invasive Gynecol. 2007;14:184-8.

Rath W. Prevention of postpartum hemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15-20.

Sweeney SG, Holbrook AM, Levine M, Yip M, Alfredsson K, Cappi S, et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Current Therapeutic Research-Clinical and Experimental. 1990;47(3):528-40.

van Dongen PW, Verbruggen MM, de Groot ANJA, van Roosmalen J, Sporken JMJ, Schulz M. Ascending dose tolerance study of intramuscular Carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol. 1998;77:181-7.

Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in non-gravid women in the reproductive years. Int J Gynaecol Obstet. 2011;113:3-13.

Yang M, Wu C, Wen X, Lin M, Li L. Using Carbetocin to prevent hemorrhage in laparoscopic myomectomy. 2012;6(27):2023-6.

Allah G, Sherine H, Wali A, Mostafa A, Shimaa. Hemostatic effect and postoperative benefits of intramyometrial Carbetocin injection during myomectomy: a randomized controlled trial. Evidence Based Women's Health J. 2015;5(4):185-9.

Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews. 2012;4.

Meshykhi LS, Nel MR, Lucas DN. The role of Carbetocin in the prevention and management of postpartum hemorrhage. Int J Obstet Anesthesia. 2016;28:61-9.

Sweeney G, Holbrook AM, Levine M. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in non-pregnant women. Curr Ther Res Clin Exper. 1990;47:528-539

Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52:60-7.

Peters NC, Duvekot JJ. Carbetocin for the prevention of postpartum hemorrhage: a systematic review. Obstet Gynecol Surv. 2009;64(2):129-35.

Engstrom T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of Carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998;355(2-3):203-10.

Rath W. Prevention of postpartum hemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15-20.

Larsson C, Saltvedt S, Wiklund I. Estimation of blood loss after caesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand. 2006;85:1448-52.

Lee MH, Ingvertsen BT, Kirpensteijn J, Jensen AL, Kristensen AT. Quantification of surgical blood loss. Vet Surg. 2006;35(4):388-93.






Original Research Articles